is it okay to switch from semaglutide to tirzepatide Switching how do i switch from

(PubMed) Kasaikina MV, Fomenko DE, Labunskyy VM, et al

Potential direct anti-inflammatory mechanisms from preclinical and early clinical studies include: Modulation of immune cell function : GLP-1 receptor activation may reduce pro-inflammatory cytokine production from macrophages and other immune cells Reduction of oxidative stress : These medications may decrease reactive oxygen species production, which contributes to inflammatory processes Endothelial protection : GLP-1 receptor agonists may improve endothelial function and reduce vascular inflammation Inhibition of inflammatory signalling pathways : Including suppression of nuclear factor-kappa B (NF-B), a key regulator of inflammatory gene expression It's important to note that many of these mechanisms have been primarily demonstrated in laboratory or animal studies, with more limited evidence in humans

A total of 389, 61, 49, 16, and 12 cases of semaglutide-associated pancreatitis, pancreatitis acute, pancreatic carcinoma, obstructive pancreatitis and pancreatic carcinoma metastatic were extracted from the FAERS database, with 333, 54, 46, 15, and 12 reported as serious cases, respectively (Table 2)

For patients with a personal history of any cancer, even if treated, resolved and with all signs removed, this is generally an area of discussion that is longer and frequently requires an oncology clearance beforehand